Nanobiotix - ADR
NBTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.8B
Close$
$-6.00
116.9% downside
Current Fair Value
116.9% downsideOvervalued by 116.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.80 Billion |
|---|---|
| Enterprise Value | $1.88 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.5 |
| Beta | 0.59 |
| Outstanding Shares | 47,819,627 |
Return
| Return on Equity | 96.06% |
|---|---|
| Return on Assets | -119.77% |
| Return on Invested Capital | -602.19% |
Valuation & Multiples
| P/E Ratio | -60.56 |
|---|---|
| PEG | 101.2 |
| Price to Sales | - |
| Price to Book Ratio | -17.77 |
| Enterprise Value to Revenue | 140.7 |
| Enterprise Value to EBIT | -30.51 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -1.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 30, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$19.92 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.92%▼ 0.11% |
|---|---|
| Total Invested | $175.90M▲ 33.46% |
| Investors Holding | 15▲ 1.00% |
ESG Score
No data
About Nanobiotix
89 employees
CEO: Laurent Levy